666260-75-9

The peripheral cannabinoid (CB₂) receptor is a G protein-coupled receptor (GPCR) that is localized predominantly in immune cells, monocytes, macrophages, and in several peripheral organs and binds the active component of cannabis, Δ⁹-tetrahydrocannabinol, as well as anandamide, an endogenous CB receptor ligand. GW 842166X is a peripheral cannabinoid (CB₂) receptor agonist with ED₅₀ values of 91 and 63 nM in rat and human, respectively. When administered orally to rats in the Freund’s complete adjuvant (FCA) model of inflammatory pain, GW 842166X is highly potent with an ED₅₀ value of 0.1 mg/kg and full reversal of hyperalgesia at 0.3 mg/kg.

GW-842166X is pyrimidine ester based compound that is known as a highly selective CB2 receptor agonist for the treatment of inflammatory and neuropathic pain.

ChEBI: 5-pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-n-[(tetrahydro-2h-pyran-4-yl)methyl]-4-(trifluoromethyl)- is a dichlorobenzene.

Store at -20°C

[1] GERARD M. P. GIBLIN. Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain[J]. Journal of Medicinal Chemistry, 2007, 50 11: 2597-2600. DOI: 10.1021/jm061195+
[2] RACHEL RIBEIRO . Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists[J]. Prostaglandins & other lipid mediators, 2013, 100: Pages 1-14. DOI: 10.1016/j.prostaglandins.2012.11.003